Inherited prion diseases are caused by mutations of the prion protein gene (*PRNP*). At least 30 single nucleotide substitutions of *PRNP* have been reported.^[@R1]^ The clinical features of patients with *PRNP* mutations are characterized by varying combinations of neurologic symptoms and signs, including weakness, spasticity, ataxia, involuntary movements, autonomic disturbance, dementia, psychiatric symptoms, and insomnia. Various names have been assigned to some of the inherited prion diseases in the literature. The existence of genotype-phenotype correlations has been suggested for these diseases.

Seven families with the missense substitution of leucine for proline at codon 105 of *PRNP* have been reported since 1993.^[@R2][@R3][@R13]^ They include 6 Japanese families and 1 British family with de novo mutation. The prominent clinical features associated with this mutation are protracted clinical duration and spastic paraparesis in addition to progressive dementia. Substantial clinical variations have also been described,^[@R2],[@R5]^ including ataxia, extrapyramidal signs, and involuntary movements.

Parkinsonism has not attracted much attention as a cardinal motor symptom in prion diseases. Only a few reports have described parkinsonism as the main symptom.^[@R2],[@R6],[@R14]^ We recently found that the *PRNP* P105L mutation is responsible for atypical parkinsonism with progressive dementia in a Japanese family and have identified 2 additional Japanese families carrying the same mutation. We herein report the clinical and molecular genetic analyses of the 3 families with the *PRNP* P105L mutation.

METHODS {#s1}
=======

Participants. {#s1-1}
-------------

In this study, we conducted clinical and molecular genetic analyses of 9 patients and 2 unaffected members of 3 families. The pedigree charts of the families are presented in [figure 1](#F1){ref-type="fig"}, and the clinical features of all the affected participants are summarized in [table 1](#T1){ref-type="table"}. The detailed clinical features of the affected individuals of the families are described briefly in appendix e-1 at [Neurology.org/ng](10.1212/NXG.0000000000000048). Genomic DNA was prepared from peripheral blood leukocytes of the participants in accordance with the standard procedure.

![Pedigree charts of 3 families with *PRNP* P105L\
Affected individuals are indicated by filled symbols. Individuals whose DNA was available are indicated by stars. "P" indicates proband.](NG2015000893FF1){#F1}

###### 

Neurologic findings and clinical features of 9 patients with *PRNP* P105L mutation

![](NG2015000893TT1)

Family 1. {#s1-2}
---------

Family history revealed that there were 11 affected members in 3 successive generations ([figure 1](#F1){ref-type="fig"}). Four affected members, III-6, III-7, III-8, and III-12, independently consulted different hospitals with which the authors were affiliated. Two of them, III-6 and III-8, were admitted to The University of Tokyo Hospital. We tentatively diagnosed them as having autosomal dominant familial parkinsonism with dementia.

The clinical features of III-8 are described below, and those of the other affected members are presented in the supplemental data. III-8 was a woman. At the age of 48 years, she started to walk slowly and stumble easily. She consulted with a neurologist at the age of 51, and neurologic examinations revealed lead-pipe rigidity of the extremities, anteflexion of the neck, postural tremor in the upper extremities, mild cognitive impairment, and emotional instability. Several antiparkinson drugs, including levodopa, zonisamide, ropinirole, and entacapone, were prescribed, but no improvement was noted. At the age of 53, her speech became weaker and faster. One year later, she began to report visual hallucinations and insomnia. On neurologic examination at the age of 54, bilateral hyperreflexia and extensor Babinski signs were noted in addition to parkinsonism and dementia. MRI showed mild diffuse atrophy of the cerebral cortex (figure e-1) with no abnormality on diffusion-weighted imaging. EEG showed background activities consisting of a low amount of slow alpha waves at 8--9 Hz intermixed with diffuse theta waves.

Family 2. {#s1-3}
---------

Family history revealed that there were 5 affected members in 2 successive generations ([figure 1](#F1){ref-type="fig"}). Three affected members, III-3, III-4, and III-5, independently consulted different hospitals with which the authors were affiliated. III-5 was admitted to The University of Tokyo Hospital.

III-3 was initially suspected of having Huntington disease. III-4 and III-5 were suspected of having atypical Parkinson disease. The clinical features of these 5 affected members are described in detail in the supplementary data. We could obtain CSF data from only 1 patient (III-5). The CSF contained 2 white blood cells/μL and 46 mg/dL protein. 14-3-3 protein level was not elevated. Total tau protein measured by ELISA and PrP^Sc^ measured by real-time quaking-induced conversion were negative. Genetic diagnosis excluded the possibilities of Huntington disease, dentatorubral-pallidoluysian atrophy, and spinocerebellar ataxia type 17. We considered it necessary to perform a differential diagnosis of Huntington disease-like diseases.

Family 3. {#s1-4}
---------

Family history revealed that there were 4 affected members in 2 successive generations ([figure 1](#F1){ref-type="fig"}). The proband of this family, III-1, consulted The University of Tokyo Hospital, followed by III-3. III-1 and III-3 were admitted to The University of Tokyo Hospital.

III-1 and III-3 were suspected of having amyotrophic lateral sclerosis/frontotemporal dementia. They later presented with parkinsonism. The clinical features of the 4 affected members are described in detail in the supplemental data.

Standard protocol approvals, registrations, and patient consents. {#s1-5}
-----------------------------------------------------------------

Written informed consent was obtained from all the participants. The present study was approved by the institutional review board of the University of Tokyo.

Whole-exome sequencing analysis. {#s1-6}
--------------------------------

Exonic sequences were enriched using SureSelect Human All Exon 50 Mb Kit (Agilent Technology, Santa Clara, CA), followed by massively parallel sequence analysis (2 × 100 bp paired-end reads) using Genome Analyzer IIx and Hiseq 2000 (Illumina, San Diego, CA). The sequences were aligned to the human reference genome (hg19) using Burrows--Wheeler Aligner.^[@R15]^ SAMtools^[@R16]^ was used for extracting single nucleotide variants (SNVs) and small insertions and deletions.

To classify the extracted SNVs with regard to novelty and pathogenicity, we checked our in-house exome database of 373 Japanese controls and the Human Gene Mutation Database (<http://www.hgmd.org/>).

Mutational analysis. {#s1-7}
--------------------

PCR was conducted using LA taq (Takara Bio, Shiga, Japan) with specific primers for *PRNP* (table e-1). Direct nucleotide sequence analyses were conducted using an ABI 3100 sequencer and BigDye Terminator v3.1 (Life Technologies, Carlsbad, CA).

Determination of the phase of the c.314C\>T (p.P105L) mutation and the c.385A\>G (p.M129V) polymorphism of *PRNP*. {#s1-8}
------------------------------------------------------------------------------------------------------------------

Genomic segments containing the c.314C\>T (p.P105L) and c.385C\>G (p.M129V) loci of *PRNP* were amplified by PCR followed by subcloning into the pTA2 vector (Toyobo, Osaka, Japan). The primer sequences are shown in table e-2. Plasmid DNA purified from 8 colonies using a QIAprep Spin Miniprep kit (Qiagen, Venlo, the Netherlands) was subjected to direct nucleotide sequence analysis to determine the phase of the c.314C\>T (p.P105L) mutation and the c.385A\>G (p.M129V) polymorphism of *PRNP*.

Haplotype analysis. {#s1-9}
-------------------

Genome-wide high-density single nucleotide polymorphism (SNP) typing was conducted on 9 patients and 2 married-in members (II-8 of family 2 and II-1 of family 3) using the Genome-Wide Human SNP array 6.0 (Affymetrix, Santa Clara, CA) following the manufacturer\'s instructions. Haplotypes were reconstructed by homozygosity haplotyping^[@R17]^ followed by visual inspection.

RESULTS {#s2}
=======

Whole-exome sequencing analyses. {#s2-1}
--------------------------------

Initially, family 1 was tentatively diagnosed as having a form of familial parkinsonism with autosomal dominant inheritance. Whole-exome sequencing analyses revealed 181,547; 182,254; and 220,616 SNVs and 16,126; 16,098; and 18,963 small insertions and deletions in III-6, III-7, and III-8 of family 1, respectively (table e-3). Of these SNVs, 10 nonsynonymous variants, which were shared by the 3 patients and were absent in 373 controls in the in-house exome database, were identified as the candidate causative mutations (table e-4). Through a search of the Human Gene Mutation Database, the heterozygous nonsynonymous substitution mutation c.314C\>T (p.P105L) in *PRNP* was found to be the only known pathogenic mutation. We confirmed by direct nucleotide sequence analyses that all 4 affected patients of family 1 carried the *PRNP* P105L mutation in a heterozygous state ([figure 2A](#F2){ref-type="fig"}).

![Identification of *PRNP* P105 and haplotype analysis of 3 families\
(A) Identification of the causative mutation in *PRNP*. The upper panel shows the aligned short reads shown using Integrative Genomics Viewer.^[@R20]^ The lower panel shows the sequence data of direct nucleotide sequence analysis. (B) Haplotypes of 3 families. Haplotypes around a *PRNP* locus are shown. Single nucleotide polymorphisms (SNPs) in the blue-shaded area are the haplotypes containing the *PRNP* P105L mutation.](NG2015000893FF2){#F2}

Mutational analysis of *PRNP*. {#s2-2}
------------------------------

Given the *PRNP* P105L mutation in family 1, we performed mutational analysis of *PRNP* in 5 patients of 2 additional families (families 2 and 3). All 5 patients had the heterozygous nonsynonymous substitution mutation c.314C\>T (p.P105L) in *PRNP*.

Intriguingly, all 9 patients had the heterozygous M129V (c.385A\>G) polymorphism of *PRNP*. There were no other variants in the coding region of *PRNP* in the 9 patients.

The phases of c.314C\>T (p.P105L) and c.385A\>G (p.M129V) in *PRNP* were determined for all the patients, as described in the Methods section. Both the mutant sequence (c.314T) and the c.385G polymorphism replacing the methionine at codon 129 with a valine were located on the same allele in all the patients (figure e-2).

Haplotype analysis. {#s2-3}
-------------------

We reconstructed the haplotypes containing the *PRNP* P105L mutation using dense SNP markers and compared the haplotypes among all 3 families. Patients in families 2 and 3 shared the common haplotype spanning 18.3 Mb around *PRNP* with telomeric and centromeric boundaries defined by rs6106883 and rs2144765, respectively. Families 1, 2, and 3 shared the common haplotype spanning 7.1 Mb around *PRNP* with telomeric and centromeric boundaries defined by rs6051365 and rs221020, respectively ([figure 2B](#F2){ref-type="fig"}).

DISCUSSION {#s3}
==========

We determined the *PRNP* c.314C\>T (p.P105L) mutation in 9 patients from3 families who presented with parkinsonism or chorea with progressive dementia with autosomal dominant inheritance. The mean age at onset was 47.2 ± 4.5 (SD) years. On average, from the time of onset, they became wheelchair bound in 5 years and bedridden in 10 years. The patients presented various motor symptoms, dementia that was attributable to a diffuse cerebral cortical dysfunction, emotional instability, and insomnia. Intriguingly, 8 patients showed parkinsonism. The patients tended to show postural tremor rather than resting tremor. Levodopa was ineffective in all patients who were prescribed it. Their disease progression was relatively rapid, and dementia developed in the early stage ([table 1](#T1){ref-type="table"}). These features are in striking contrast to the clinical features of idiopathic Parkinson disease.

The age at onset and disease duration of the patients were similar to those of the previously reported cases of the *PRNP* P105L mutation. However, the clinical features of previously reported cases were spastic paraparesis and progressive dementia. Only 3 reports described parkinsonism as the main symptom.^[@R2],[@R6],[@R14]^ [Figure 3](#F3){ref-type="fig"} shows a summary of neurologic findings of our 9 patients and previously reported cases. The present study revealed that the main symptoms of P105L prion disease were not only spastic paraparesis but also parkinsonism.

![Prevalence of neurologic findings in 20 patients with *PRNP* P105\
Neurologic findings of previously reported patients (10), our reported patients (9), and their family member (1). We summarized only members from whom we were able to obtain detailed neurologic findings. Black bars indicate previously reported patients. Gray bars indicate newly diagnosed patients. Seven patients had tremor, 4 of whom had postural tremor.](NG2015000893FF3){#F3}

This study further broadened the spectrum of the clinical presentations of patients with the *PRNP* P105L mutation. Because they showed a long disease course and did not show myoclonus or periodic synchronous discharges on EEG, elevated tau and 14-3-3 levels, or high-intensity signal on diffusion-weighted MRI, it took a long time for our patients to be diagnosed with P105L prion disease. Because they presented mainly with parkinsonism, an inherited prion disease with the *PRNP* P105L mutation should be considered as a differential diagnosis of atypical familial parkinsonism with dementia. The famous Indiana kindred of Gerstmann-Sträussler-Scheinker syndrome with the *PRNP* F198S mutation presented with progressive ataxia, dementia, and parkinsonian features. Patients in this kindred tend to present with dementia and cerebellar ataxia early in the disease and rigidity and bradykinesia later in the disease.^[@R18]^ Rare variants in the octarepeat region of the *PRNP* gene have been found in patients with parkinsonism,^[@R19]^ but there were no variants in the octarepeat region of the *PRNP* gene in our patients. We have not performed the functional brain imaging tests of dopamine transporters in all our patients. Autopsies were performed for some patients with the *PRNP* P105L mutation.^[@R4],[@R6],[@R9],[@R11]^ PrP plaques and neuronal loss were observed in the basal ganglia in the terminal phase regardless of the presence of extrapyramidal symptoms. These pathologic findings in the basal ganglia might be related to parkinsonian features of the patients with the *PRNP* P105L mutation.

The 3 families shared a long common haplotype around *PRNP*, which spanned at least 1.8 Mb, suggesting that they were descendants from a common ancestor. All our patients had the mutation sequence (c.314T, P105L) and the polymorphism (c.385G, p.M129V) on the same haplotype. All the other previously reported cases had the Val 129 polymorphism, although the phase of the P105L mutation and the Val 129 polymorphism of *PRNP* on the same allele was confirmed in only 1 study.^[@R8]^ The allele frequency of Val 129 in the Japanese population is 0.04 according to the Human Genetic Variation Database (<http://www.genome.med.kyoto-u.ac.jp/SnpDB/>). Consequently, the existence of a very strong linkage disequilibrium between the Leu 105 mutation allele and the rare Val 129 polymorphic allele in previously reported cases suggests that all Japanese patients might have a common founder.

There were phenotypic variations of patients in families with the *PRNP* P105L mutation. The variants of genes other than *PRNP*, for example, genes related to the degradation and elimination pathways of prion protein, might influence the phenotype of patients with the *PRNP* P105L mutation as genetic modifying factors. We need further studies to elucidate the phenotypic variations of patients with inherited prion disease.

Supplementary Material
======================

###### Data Supplement

Supplemental data at [Neurology.org/ng](10.1212/NXG.0000000000000048)
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